← Back to patent-cliff list
CG001419
Tier C — Watch / tradeCG001419
Cullgen Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Trk
Indications (approved)：Solid tumour, Pain
Regional status
US
-
EU
-
China
Phase II
2023-06-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CG001419?
Approved indications include: Solid tumour, Pain.
When does the CG001419 patent expire?
No public expiry year is available for CG001419 yet; this page updates once verified.
How do I get a quote for CG001419 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21